Shivali Rajput, 43, excels in her job, earns well and overshoots her career targets year after year. But when it comes to managing her weight, Rajput’s efforts have come a cropper, year after year. She is 102 kg, about 25 kg above the average weight in her age group. She is at her wit’s end but the thought of going under the knife gives her the jitters. So last week she was at the clinic of a Delhi-based diabetician, asking if she could be put on weight-loss drugs.
About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows
HYDERABAD, April 18 (Reuters) - Indian drugmaker Biocon (BION.NS), opens new tab, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's (NOVOb.CO), opens new tab wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters.
Biotechnology firm Biocon on Wednesday said it has tied up with Brazil-based Biomm SA for the commercialisation of its diabetes drug in the Latin American nation. Under the terms of the agreement, Biocon will undertake the development, manufacturing and supply of Semaglutide (gOzempic), and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market.
EU regulator rules out link between weight-loss drugs and suicidal thoughts
April 11 (Reuters) - German packaging and medical equipment maker Gerresheimer (GXIG.DE), opens new tab expects diabetes and diet drugs to contribute 350 million euros ($376 million) of annual revenue by the 2026/27 financial year, CFO Bernd Metzner told Reuters after the company reported first-quarter results on Thursday.
April 11 (Reuters) - German packaging and medical equipment maker Gerresheimer (GXIG.DE), opens new tab is contracted to supply key players in the market for GLP-1 weight loss drugs, its CEO Dietmar Siemssen said on Thursday.
Novo Nordisk parent refiles US application on Catalent deal
China`s first biosimilar Ozempic drug applies for approval
Eisai, Biogen`s subQ Leqembi delayed amid FDA`s data request